N/A
Completed N=1
Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use
Source: ClinicalTrials.gov NCT01648491 ↗Enrolled (actual)
1
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcomePrimary: Study-Related Adverse Events — 0 Adverse Events
Summary
Determine safety and effectiveness of the technique using autologous stem cells in the treatment of urinary incontinence in one male subject.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Study-Related Adverse Events |
— | — |
| SECONDARY Quality of Life (QOL) Described by the Patient's Response on the Patient Global Assessment of Severity (PGI-S) Questionnaire |
4; 4; 5; 6 | — |
| SECONDARY Quality of Life (QOL) Described by the Patient's Response on the Global Response Assessment (GRA) |
4 | — |
| SECONDARY Quality of Life (QOL) Described by the Patient's Response on the Patient Global Impression of Improvement (PGI-I) |
4 | — |
Eligibility Criteria
Inclusion Criteria
- urinary incontinence
- failed urinary incontinence (UI) treatments
Exclusion Criteria
- does not meet inclusion criteria, gender and age limit
Data sourced from ClinicalTrials.gov (NCT01648491). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.